We previously discovered a new osteogenic growth factor that is required to maintain adult skeletal bone mass, Osteolectin/Clec11a. Osteolectin acts on Leptin Receptor + (LepR + ) skeletal stem cells and other osteogenic progenitors in bone marrow to promote their differentiation into osteoblasts. Here we identity a receptor for Osteolectin, a11 integrin, which is expressed by LepR + cells and osteoblasts. a11b1 integrin binds Osteolectin with nanomolar affinity and is required for the osteogenic response to Osteolectin. Deletion of Itga11 (which encodes a11) from mouse and human bone marrow stromal cells impaired osteogenic differentiation and blocked their response to Osteolectin. Like Osteolectin deficient mice, Lepr-cre; Itga11 fl/fl mice appeared grossly normal but exhibited reduced osteogenesis and accelerated bone loss during aging. Osteolectin binding to a11b1 promoted Wnt pathway activation, which was necessary for the osteogenic response to Osteolectin. This reveals a new mechanism for maintenance of adult bone mass: Wnt pathway activation by Osteolectin/a11b1 signaling.
INTRODUCTION
The maintenance of the adult skeleton requires the formation of new bone throughout life from the differentiation of skeletal stem/progenitor cells into osteoblasts. Leptin Receptor + (LepR + ) bone marrow stromal cells are the major source of osteoblasts and adipocytes in adult mouse bone marrow . These cells arise postnatally in the bone marrow, where they are initially rare and make little contribution to the skeleton during development, but expand to account for 0.3% of cells in adult bone marrow (Mizoguchi et al., 2014; Zhou et al., 2014) . Nearly all fibroblast colony-forming cells (CFU-F) in adult mouse bone marrow arise from these LepR + cells, and a subset of LepR + cells form multilineage colonies with osteoblasts, adipocytes, and chondrocytes, suggesting they are highly enriched for skeletal stem cells . LepR + cells are also a critical source of growth factors that maintain hematopoietic stem cells and other primitive hematopoietic progenitors in mouse bone marrow (Ding and Morrison, 2013; Ding et al., 2012; Himburg et al., 2018; Oguro et al., 2013) .
To identify new growth factors that regulate hematopoiesis or osteogenesis, we performed RNA-Seq analysis on LepR + cells and looked for transcripts predicted to encode secreted proteins with sizes and structures similar to growth factors and whose function had not been studied in vivo. We discovered that Clec11a, a secreted glycoprotein of the C-type lectin domain superfamily (Bannwarth et al., 1999; Bannwarth et al., 1998) , was preferentially expressed by LepR + cells (Yue et al., 2016) . Prior studies had observed Clec11a expression in bone marrow but inferred based on colony-forming assays in culture that it was a hematopoietic growth factor (Hiraoka et al., 1997; Hiraoka et al., 2001) . We made germline knockout mice and found it is not required for normal hematopoiesis but that it is required for the maintenance of the adult skeleton (Yue et al., 2016) . The mutant mice formed their skeleton normally during development and were otherwise grossly normal as adults but exhibited reduced adult osteogenesis and accelerated bone loss during aging (Yue et al., 2016) . Recombinant protein promoted osteogenic differentiation by bone marrow stromal cells in vitro and in vivo (Yue et al., 2016) . Based on these observations we proposed to call this new osteogenic growth factor, Osteolectin, so as to have a name related to its biological function. Osteolectin/Clec11a is expressed by a subset of LepR + stromal cells in the bone marrow as well as by osteoblasts, osteocytes, and hypertrophic chondrocytes. The discovery of Osteolectin offers the opportunity to better understand the mechanisms that maintain the adult skeleton; however, the Osteolectin receptor and the signaling mechanisms by which it promotes osteogenesis are unknown.
Several families of growth factors, and the signaling pathways they activate, promote osteogenesis, including Bone Morphogenetic Proteins (BMPs), Fibroblast Growth Factors (FGFs), Hedgehog proteins, Insulin-Like Growth Factors (IGFs), Transforming Growth Factorbetas (TGF-bs), and Wnts (reviewed by (Karsenty, 2003; Kronenberg, 2003; Wu et al., 2016) .
Bone marrow stromal cells regulate osteogenesis by skeletal stem/progenitor cells by secreting multiple members of these growth factor families (Chan et al., 2015) . The Wnt signaling pathway is a particularly important regulator of osteogenesis, as GSK3 inhibition and b-catenin accumulation promote the differentiation of skeletal stem/progenitor cells into osteoblasts (Bennett et al., 2005; Dy et al., 2012; Hernandez et al., 2010; Krishnan et al., 2006; Kulkarni et al., 2006; Rodda and McMahon, 2006) . Consistent with this, mutations that promote Wnt pathway activation increase bone mass in humans and in mice (Ai et al., 2005; Balemans et al., 2001; Boyden et al., 2002) while mutations that reduce Wnt pathway activation reduce bone mass in humans and in mice (Gong et al., 2001; Holmen et al., 2004; Kato et al., 2002) .
There are 18 integrin a subunits and 8 b subunits, forming 24 different functional integrin heterodimer complexes (Humphries et al., 2006; Hynes, 1992) . Integrin signaling is known to promote Wnt pathway activation through Integrin-Linked Kinase (ILK)-mediated phosphorylation of GSK3 and nuclear translocation of b-catenin (Burkhalter et al., 2011; Delcommenne et al., 1998; Novak et al., 1998; Rallis et al., 2010) . Conditional deletion of ILK or Focal Adhesion Kinase (FAK) from osteoblast progenitors reduces osteogenesis and depletes trabecular bone in adult mice (Dejaeger et al., 2017; Sun et al., 2016) , suggesting a role for integrins in adult osteogenesis. Conditional deletion of b1 integrin from chondrocytes or skeletal stem/progenitor cells impairs chondrocyte function and skeletal ossification during development (Aszodi et al., 2003; Raducanu et al., 2009; Shekaran et al., 2014) . Activation of avb1 signaling by Osteopontin (Chen et al., 2014) or a5b1 signaling by Fibronectin (Hamidouche et al., 2009; Moursi et al., 1997) promotes the osteogenic differentiation of mesenchymal progenitors.
Germline deletion of integrin a10 leads to defects in chondrocyte proliferation and growth plate function (Bengtsson et al., 2005) and germline deletion of integrin a11 leads to defects in tooth development (Popova et al., 2007) . However, little is known about which integrins are required for adult osteogenesis in vivo.
RESULTS

Integrin a11 is selectively expressed by LepR+ cells and osteoblasts
The Osteolectin/Clec11a gene first appeared in bony fish and is conserved among bony vertebrates (Yue et al., 2016) . Osteolectin contains a glutamic acid-rich sequence, an alphahelical leucine zipper, and a C-type lectin domain ( Figure 1A and 1B) (Bannwarth et al., 1999; Bannwarth et al., 1998) . To generate hypotheses regarding potential Osteolectin receptors, we examined the amino acid sequence and found two integrin-binding motifs, RGD (Gardner and Hynes, 1985; Pierschbacher and Ruoslahti, 1984; Plow et al., 1985) and LDT (Fong et al., 1997; Viney et al., 1996) in human ( Figure 1A ) and mouse Osteolectin ( Figure 1B ). One or both of these motifs were conserved across Osteolectin sequences in all bony vertebrates ( Figure 1C ).
This raised the possibility that the Osteolectin receptor might be an integrin.
We hypothesized that the Osteolectin receptor would be restricted in its expression to osteogenic cells in the bone marrow, so we examined the expression of all a and b integrins in mouse bone marrow stromal cells by RNA-seq analysis. Among the genes that encode a integrins, Itga1 (encoding a1), Itga6 (encoding a6), Itga11 (encoding a11) and ItgaV (encoding aV), were strongly expressed by bone marrow stromal cells ( Figure 1D ). Among the genes that encode b integrins, only Itgb1 (encoding b1) was strongly expressed by bone marrow stromal cells ( Figure 1E ). To refine potential candidate receptors for Osteolectin we more closely examined the expression of these genes in LepR + cells, which are osteogenic and should express the receptor, and endothelial cells, which are not osteogenic and should not express the receptor. Itga1, Itga6, and ItgaV were strongly expressed by both LepR + cells and endothelial cells, suggesting they did not encode the receptor ( Figure 1F ). Itga11 was expressed exclusively by LepR + cells, not by endothelial cells or other bone marrow cells ( Figure 1F ). We next examined Itga11 expression in a number of sorted bone marrow cell populations by quantitative reverse transcription PCR (qRT-PCR) ( Figure S1 shows the markers used to isolate these cell populations). We found that Itga11 was highly expressed by LepR + CD45 -Ter119 -CD31stromal cells and Col2.3-GFP + CD45 -Ter119 -CD31osteoblasts but not by any hematopoietic stem or progenitor population ( Figure 1G ). The expression patterns of Itga11 and Itgb1 are thus consistent with a potential role in osteogenesis.
Consistent with our results, integrin a11 is expressed by human bone marrow stromal cells in a way that correlates with osteogenic potential in culture (Kaltz et al., 2010) ; however, a11 is not known to regulate osteogenesis. Integrin a11 heterodimerizes with integrin b1 (Velling et al., 1999) and the only known ligand for a11b1 is collagen (Popova et al., 2004; Velling et al., 1999) . Few cells express integrin a11 and it has been studied less than other integrins. Itga11 deficient mice are growth retarded and have smaller bones, but this was thought to be a consequence of a defect in incisor development that leads to malnutrition (Popova et al., 2007) .
Osteolectin binds to a11b1 with nanomolar affinity
To begin to test whether a11b1 binds Osteolectin, we overexpressed human Osteolectin with a C-terminal Flag tag in MC3T3-E1 pre-osteoblast cells and immunoprecipitated with anti-Flag beads. The anti-Flag beads pulled down the tagged Osteolectin along with endogenous integrin a11 ( Figure 1H ). We then tested the affinity of recombinant human Osteolectin for multiple recombinant human integrin complexes by a microtiter well binding assay. Osteolectin selectively bound to integrin a11b1 and a10b1, but not to other integrins, including aVb1, aVb3, a4b1, a9b1, aIIbb3 or aMb3 ( Figure 1I ). Integrin a10 is the gene most closely related to a11.
Integrin a10 is expressed by osteoblasts and chondrocytes (Bengtsson et al., 2005; Engel et al., 2013 ) but only at a low level by bone marrow stromal cells ( Figure 1D ). The dissociation constant (kd) of Osteolectin for a10b1 and a11b1 was 0.3nM whereas the kd of Osteolectin for other integrins was >100nM. The kd of human Pro-Collagen 1a for a11b1 was also high (0.1nM; Figure 1J ); however, in contrast to Osteolectin, addition of Pro-Collagen 1a to culture did not promote osteogenesis by MC3T3-E1 cells or two primary human bone marrow stromal cell lines (hBMSC#1 or hBMSC#2; Figure 1K ).
Osteolectin promotes Wnt pathway activation
MC3T3-E1 cells, hBMSC#1 cells, and hBMSC#2 cells secrete Osteolectin into the culture medium ( Figure 2A ), consistent with our observation that Osteolectin is synthesized by a subset of LepR + bone marrow stromal cells (Yue et al., 2016) . Deletion of Osteolectin from these cell lines reduced their osteogenic differentiation in osteogenic differentiation medium ( Figure 2B ), demonstrating that autocrine Osteolectin production is part of what drives osteogenesis by these cells in culture.
To assess the signaling mechanisms by which Osteolectin promotes osteogenesis, we treated parental MC3T3-E1 cells, hBMSC#1 cells, and hBMSC#2 cells with recombinant Osteolectin and assessed the levels of phosphorylated PI3-kinase, Akt, and GSK3. The most prominent change we observed was a dramatic increase of GSK3 phosphorylation at Ser21/9 within 30 to 60 minutes of Osteolectin treatment in all three cell lines ( Figure 2C ).
Phosphorylation at Ser21/9 inhibits the GSK3-mediated degradation of b-catenin, increasing bcatenin levels and promoting the transcription of Wnt pathway target genes (Cross et al., 1995; Peifer et al., 1994; Yost et al., 1996) . We did not observe an increase in b-catenin levels within 1 hour of Osteolectin treatment, but did detect increased b-catenin levels in all three cell lines within 24 hours of Osteolectin treatment ( Figure 2D ). The transcription of several Wnt target genes, including Axin2 (Jho et al., 2002; Lustig et al., 2002; Yan et al., 2001; Yan et al., 2009 ), Lef1 (Filali et al., 2002 Gaur et al., 2005; Hovanes et al., 2001 ), Runx2 (Dong et al., 2006 Gaur et al., 2005) , and Alkaline phosphatase (Rawadi et al., 2003) , were activated within 24 hours of Osteolectin treatment ( Figure 2E ). Osteolectin deficient MC3T3-E1 cells, hBMSC#1 cells, and hBMSC#2 cells had lower levels of phospho-GSK3 and b-catenin as compared to parental cells ( Figure 2F ) as well as significantly lower levels of Wnt target genes ( Figure 2G ). These data demonstrate that Osteolectin promotes Wnt pathway activation in osteogenic cells.
Osteogenesis in response to Osteolectin requires b-catenin
To test whether Wnt pathway activation phenocopies the effects of Osteolectin, we evaluated the effects of AZD2858, which inhibits GSK3 function and promotes b-catenin accumulation (Berg et al., 2012) . As expected (Gilmour et al., 2013; Marsell et al., 2012; Sisask et al., 2013) , AZD2858 increased GSK3 phosphorylation and b-catenin levels ( Figure 3A ) as well as osteogenic differentiation ( Figure 3B ) by MC3T3-E1 cells, hBMSC#1 cells, and hBMSC#2 cells. Osteolectin also increased GSK3 phosphorylation, b-catenin levels, and osteogenic differentiation by MC3T3-E1 cells, hBMSC#1 cells, and hBMSC#2 cells ( Figure 3A and 3B). However, when the two agents were added together, there was no further promotion of osteogenic differentiation beyond the effects of the individual agents ( Figure 3B ). These data suggest that Osteolectin and GSK3/b-catenin act in the same pathway to promote osteogenic differentiation by mesenchymal progenitors.
To test whether Osteolectin requires b-catenin to promote osteogenesis, we evaluated an inhibitor of Wnt pathway signaling, IWR-1-endo, which depletes b-catenin by stabilizing Axin2 in the b-catenin destruction complex (Chen et al., 2009) . As expected, Osteolectin increased b-catenin levels and osteogenesis by MC3T3-E1 cells, hBMSC#1 cells, and hBMSC#2 cells while IWR-1-endo reduced b-catenin levels and osteogenesis ( Figure 3C and 3D). When added together, IWR-1-endo blocked the effect of Osteolectin on b-catenin levels and osteogenesis ( Figure 3C and 3D). This suggests that Osteolectin requires b-catenin to induce osteogenesis by mesenchymal progenitors.
Wnt pathway activation and osteogenesis by Osteolectin require a11 integrin
To test if Integrin a11 is required for the osteogenic response to Osteolectin, we used CRISPR/Cas9 to delete Itga11 from MC3T3-E1 cells, hBMSC#1 cells, and hBMSC#2 cells.
Deletion of Itga11 from MC3T3-E1 cells, hBMSC#1 and hBMSC#2 cells significantly reduced osteogenesis by each cell line in culture ( Figure 4A ). Addition of recombinant Osteolectin to culture significantly promoted osteogenesis by parental, but not Itga11 deficient, MC3T3-E1, hBMSC#1, and hBMSC#2 cells ( Figure 4A ). Integrin a11 is therefore required by mouse and human bone marrow stromal cells to undergo osteogenesis in response to Osteolectin.
The Itga11 deficient MC3T3-E1 cells, hBMSC#1 cells, and hBMSC#2 cells also exhibited lower levels of GSK3 phosphorylation and b-catenin as compared to parental control cells ( Figure 4B ). Addition of recombinant Osteolectin to culture increased the levels of phosphorylated GSK3 and b-catenin in parental control cells but not in Itga11 deficient cells ( Figure 4B ). Consistent with the reduced levels of phosphorylated GSK3 and b-catenin in the Itga11 deficient cells, we also observed significantly lower levels of Wnt target gene transcripts in the Itga11 deficient cells ( Figure 4C ). Addition of recombinant Osteolectin to culture significantly increased the levels of Wnt target gene transcripts in parental control cells but not in Itga11 deficient cells ( Figure 4C ). Integrin a11 is therefore required by mouse and human bone marrow stromal cells to activate Wnt pathway signaling in response to Osteolectin.
Given that Collagen 1a bound to a11b1 ( Figure 1J ) but did not promote osteogenesis by MC3T3-E1 cells, hBMSC#1 cells, or hBMSC#2 cells ( Figure 1K ), we tested whether Collagen 1a promoted Wnt pathway activation in these cells. Addition of recombinant Osteolectin to culture increased levels of phosphorylated GSK3, b-catenin, and Wnt target gene transcripts in MC3T3-E1 cells, hBMSC#1 cells, and hBMSC#2 cells ( Figure 4D and 4E); however, addition of Pro-Collagen 1a to these cells did not seem to have any effect on the levels of phosphorylated GSK3, b-catenin, or Wnt target gene transcripts ( Figure 4D and 4E). Exogenous Pro-Collagen 1a, therefore, did not activate Wnt pathway signaling in mouse or human bone marrow stromal cells, offering a potential explanation for its failure to promote osteogenesis by these cells.
Conditional deletion of Integrin a11 from LepR + cells reduces osteogenesis in vivo
To test whether Integrin a11 is necessary for osteogenesis in vivo we generated mice bearing a floxed allele of Itga11 ( Figure S5A -C), then conditionally deleted it from skeletal stem and progenitor cells in the bone marrow using Lepr-Cre. Lepr-Cre; Itga11 fl/fl mice did not exhibit the defects in incisor development (data not shown) or the growth retardation observed in germline Itga11 -/mice (Popova et al., 2007) . Lepr-Cre; Itga11 fl/fl mice appeared grossly normal ( Figure 5A ), with body lengths ( Figure 5B ), body masses ( Figure 5C ), and femur lengths ( Figure   5D ) that did not significantly differ from sex-matched littermate controls. Serum Osteolectin levels did not significantly differ between Lepr-Cre; Itga11 fl/fl mice and littermate controls at 2 or 12 months of age but were modestly higher in Lepr-Cre; Itga11 fl/fl mice as compared to controls at 6 months of age ( Figure 5E ). This demonstrates that Integrin a11 is not required for the synthesis or secretion of Osteolectin.
To test whether deletion of Itga11 from LepR + cells affected osteogenesis in vivo, we performed micro-CT analysis of the distal femur from 2, 6, and 12-month old Lepr-Cre; Itga11 fl/fl mice and sex-matched littermates. Consistent with the observation that LepR + cells and Osteolectin contribute little to skeletal development (Yue et al., 2016; Zhou et al., 2014) , we observed no significant difference in trabecular bone parameters between Lepr-Cre; Itga11 fl/fl mice and sex-matched littermates at 2 months of age ( Figure 5F -L). However, LepR + cells and Osteolectin are necessary for adult osteogenesis (Yue et al., 2016; Zhou et al., 2014) .
Consistent with this, 6 and 12-month-old male and female Lepr-Cre; Itga11 fl/fl mice had significantly reduced trabecular bone volume as compared to sex-matched littermate controls ( Figure 5F and 5G). At 6 and 12 months of age, male and female Lepr-Cre; Itga11 fl/fl mice also tended to have significantly lower trabecular number ( Figure 5H ) and trabecular thickness ( Figure 5I ) than sex matched littermate controls. Calcein double labelling showed that the mineral apposition rate was significantly reduced in trabecular bone from Lepr-Cre; Itga11 fl/fl mice as compared to sex-matched littermates at 6 and 12 months of age ( Figure 5M ). Integrin a11 is, therefore, required by LepR + cells and their progeny for normal rates of trabecular bone formation and maintenance of trabecular bone mass during adulthood, phenocopying the accelerated trabecular bone loss in adult Osteolectin deficient mice (Yue et al., 2016) .
While Lepr-Cre; Itga11 fl/fl mice had significantly reduced rates of bone formation as compared to sex-matched littermates ( Figure 5M ), they did not significantly differ in the urinary bone resorption marker deoxypyridinoline at 6 or 12 months of age ( Figure 5N ; this was not tested in 2-month-old mice because no difference in bone parameters was observed at that age). This suggests that, like Osteolectin, Integrin a11 promotes bone formation but does not regulate bone resorption.
Osteolectin deficiency has a milder effect on cortical bone as compared to trabecular bone, with no significant reduction in cortical bone until after 10 months of age (Yue et al., 2016) . Consistent with this, femur cortical bone parameters did not significantly differ between Lepr-Cre; Itga11 fl/fl mice and sex-matched littermates at 2 or 6 month of age ( Figure 6A -F).
However, cortical thickness, cortical area, and cortical bone mineral density were significantly lower in male Lepr-Cre; Itga11 fl/fl mice as compared to sex-matched littermates at 12 months of age ( Figure 6D -F). The differences in these parameters between female Lepr-Cre; Itga11 fl/fl mice and littermate controls were not statistically significant ( Figure 6D -F). Calcein double labelling revealed that the mineral apposition rate was significantly reduced in cortical bone from male and female Lepr-Cre; Itga11 fl/fl mice as compared to sex-matched littermate controls at 6 and 12 months of age ( Figure 6G ). Deletion of Integrin a11 from LepR + cells thus reduces the rate of cortical bone formation during adulthood, slowly leading to a thinning of cortical bone that became apparent in the femurs of male mice at 12 months of age, phenocopying the slow loss of cortical bone in adult Osteolectin deficient mice (Yue et al., 2016) .
Integrin a11 is required in bone marrow stromal cells to respond to Osteolectin
To test whether Integrin a11 is necessary for the maintenance or the proliferation of skeletal stem/progenitor cells in the bone marrow, we cultured at clonal density enzymatically dissociated femur bone marrow cells from Lepr-Cre; Itga11 fl/fl and sex-matched littermate control mice at 2 and 6 months of age. We observed a slight, but statistically significant, reduction in the frequency of cells that formed CFU-F colonies in Lepr-Cre; Itga11 fl/fl mice at 2 months of age, though no significant difference was apparent at 6 months of age ( Figure 7A ). We observed no significant difference in the number of cells per colony at either age ( Figure 7B ). Integrin a11 is therefore not required for the maintenance of CFU-F in vivo or for their proliferation in vitro. To test whether integrin a11 regulates the differentiation of bone marrow stromal cells, we cultured CFU-F from Lepr-Cre; Itga11 fl/fl and littermate control mice at clonal density, then replated equal numbers of cells from Itga11 deficient and control colonies into osteogenic or adipogenic culture conditions ( Figure 7C and 7D). We also centrifuged 2 x 10 5 CFU-F cells from Lepr-Cre; Itga11 fl/fl and control colonies to form pellets and then cultured them in chondrogenic medium ( Figure   7E ). Consistent with the decreased osteogenesis from Itga11 deficient mesenchymal cell lines in culture ( Figure 4A ) and the reduced osteogenesis in Lepr-Cre; Itga11 fl/fl mice in vivo ( Figure 5 and Figure 6 ), bone marrow stromal cells from Lepr-Cre; Itga11 fl/fl mice formed significantly less bone in culture as compared to control colonies ( Figure 7C ). This demonstrates that, like Osteolectin, Integrin a11 promotes osteogenesis by bone marrow stromal cells. We did not detect any difference between Lepr-Cre; Itga11 fl/fl and control colonies in adipogenic or chondrogenic differentiation ( Figure 7D and 7E ). This is also consistent with the Osteolectin deficiency phenotype, which reduced osteogenesis in vitro and in vivo without having any detectable effect on adipogenesis or chondrogenesis (Yue et al., 2016) .
To test whether Integrin a11 is necessary for the osteogenic response of bone marrow stromal cells to Osteolectin, we cultured CFU-F from the bone marrow of 2-month-old Lepr-Cre; Itga11 fl/fl mice and littermate controls then added osteogenic differentiation medium with or without recombinant mouse Osteolectin. Osteolectin significantly increased osteogenic differentiation by control colonies, but Lepr-Cre; Itga11 fl/fl colonies underwent significantly less osteogenesis and did not respond to Osteolectin ( Figure 7F ). Bone marrow stromal cells thus require Integrin a11 to undergo osteogenesis in response to Osteolectin in culture.
To test if bone marrow stromal cells require Integrin a11 to undergo osteogenesis in response to Osteolectin in vivo, we administered daily subcutaneous injections of recombinant mouse Osteolectin to 2-month-old Lepr-Cre; Itga11 fl/fl and littermate control mice for 28 days.
Consistent with our prior study (Yue et al., 2016) , in the distal femur metaphysis of control mice, Osteolectin treatment significantly increased trabecular bone volume ( Figure 7G Figure 7N ). Addition of AZD2858 significantly increased osteogenic differentiation from both Lepr-Cre; Itga11 fl/fl and control stromal cells. In cultures treated with DMSO control, Lepr-Cre; Itga11 fl/fl stromal cells had lower levels of phosphorylated GSK3 and b-catenin as compared to control stromal cells ( Figure 7O ). AZD2858 increased the levels of phosphorylated GSK3 and b-catenin in both Lepr-Cre; Itga11 fl/fl and control stromal cells ( Figure 7O ). Lepr-Cre; Itga11 fl/fl stromal cells thus retain the ability to undergo osteogenesis in response to Wnt pathway activation, even though they do not respond to Osteolectin.
DISCUSSION
Our data demonstrate that integrin a11 is a physiologically important receptor for Osteolectin, mediating its effect on osteogenesis. Integrin a11 is expressed by LepR + skeletal stem cells and osteoblasts but shows limited expression in non-osteogenic cells ( Figure 1G ).
Osteolectin bound selectively to a11b1 integrin, with nanomolar affinity ( Figure 1I and 1J Figure 7N and 7O). We conclude that a11 integrin is required by skeletal stem/progenitor cells to undergo osteogenesis in response to Osteolectin.
While deficiency for a11 integrin phenocopied the effects of Osteolectin deficiency, we do not rule out a potential role for a10 integrin in mediating certain effects of Osteolectin. a10b1 also bound Osteolectin with nanomolar affinity ( Figure 1I ). Integrin a11 is more highly expressed than a10 by LepR + cells ( Figure 1D ); however, integrin a10 is expressed by chondrocytes (Bengtsson et al., 2005; Reinisch et al., 2015) . While we did not observe any cartilage defects in Osteolectin deficient mice (Yue et al., 2016) , Osteolectin may promote the differentiation of hypertrophic chondrocytes into bone in adult mice, such as during fracture healing. Therefore, a10 integrin may mediate the effects of Osteolectin on hypertrophic chondrocytes while a11 integrin may mediate the effects of Osteolectin on skeletal stem/progenitor cells.
Osteolectin may not be the only osteogenic ligand for a11 integrin. Collagen is a known ligand for a11b1 integrin (Popova et al., 2007) . We found that collagen binds to a11b1 with nanomolar affinity ( Figure 1J ) but did not detect any effect of exogenous collagen on Wnt pathway activation ( Figure 4E ) or osteogenic differentiation ( Figure 1K ). This suggests that collagen may bind a11b1 in a way that regulates cell adhesion and migration but not Wnt pathway activation, at least in skeletal stem/progenitor cells. Alternatively, endogenous collagen may bind a11b1 differently than exogenous collagen, potentially even promoting osteogenesis.
Since Lepr-Cre; Itga11 fl/fl mice delete Itga11 in postnatal bone marrow mesenchymal cells that exhibit little contribution to the skeleton during development , it remains untested whether a11 integrin regulates osteogenesis during development. If so, this would raise the possibility of a distinct osteogenic ligand for a11 during development as Osteolectin deficient mice do not appear to exhibit defects in skeletal development (Yue et al., 2016) .
Finally, the osteogenic effect of a11 integrin in mesenchymal cells may not be the only function for a11 integrin. While it is not widely expressed by other cell types, a11 integrin may have other functions in non-mesenchymal cells, or during development, in cells that are not competent to undergo osteogenesis. Integrin a11 is expressed by periodontal ligament fibroblasts and is required for the migration of these cells during ligament development, leading to a failure of tooth eruption in germline a11 deficient mice (Popova et al., 2007) . This raises the possibility that collagen binding to a11b1 may have biologically distinct consequences in cells that are not competent to form bone.
In conclusion, we identify a11 integrin as an Osteolectin receptor and a new regulator of osteogenesis and adult skeleton maintenance. The identification of a new ligand/receptor pair that regulates the maintenance of the adult skeleton offers the opportunity to better understand the physiological and pathological mechanisms that influence skeletal homeostasis.
MATERIALS AND METHODS
Mice and cell lines
To generate Itga11 fl/fl mice, CleanCap™ Cas9 mRNA (TriLink) and sgRNAs (transcribed using MEGAshortscript Kit (Ambion), purified using the MEGAclear Kit (Ambion)), and recombineering plasmids were microinjected into C57BL/Ka zygotes. Chimeric mice were genotyped by restriction fragment length poly-morphism (RFLP) analysis and confirmed by Southern blotting and sequencing of the targeted allele. The mice were backcrossed onto a C57BL/Ka background to obtain germline transmission. Mutant mice were backcrossed onto a C57BL/Ka background for at least 3 generations prior to analysis. All procedures were approved by the UTSW Institutional Animal Care and Use Committee (protocol number 2016-101334-G).
Cell lines used in this study included mouse preosteoblast MC3T3-E1 cells (Subclone 4, ATCC CRL-2593), human bone marrow stromal cells from ATCC (PCS-500-012; referred to as hBMSC#1), and human bone marrow stromal cells from Lonza (PT-2501, referred to as hBMSC#2). MC3T3-E1 cells were cultured in Alpha Minimum Essential Medium with ribonucleosides, deoxyribonucleosides, 2 mM L-glutamine and 1 mM sodium pyruvate, but without ascorbic acid (GIBCO, A1049001) supplemented with 10% fetal bovine serum (Sigma, F2442) and penicillin-streptomycin (HyClone). MC3T3-E1 cells were only used for experiments before passage 20. hBMSC cells were cultured in low glucose DMEM (Gibco) supplemented with 20% fetal bovine serum (Sigma, F2442) and penicillin-streptomycin (HyClone), and were only used for experiments before passage 16.
Western blots
Cells were cultured until confluent, then transferred into osteogenic differentiation medium with or without Osteolectin or small molecule inhibitors of Wnt pathway components.
Prior to extracting proteins, cells were washed with PBS and then lysis buffer was added containing 50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM sodium vanadate, 0.5 mM sodium fluoride, and cOmplete Mini EDTA-free Protease Inhibitor Cocktail (Sigma). The cells were scraped off the plate in the lysis buffer, transferred to an Eppendorf tube on ice, incubated for 20 minutes with occasional vortexing, then centrifuged at 17,000xg for 10 minutes at 4°C to clear cellular debris. The cell lysates were Western blotted with the indicated antibodies and immunoreactive bands were detected using ECL reagent 
PCR genotyping
To genotype Itga11 floxed mice the following primers were used: 5'-AATTCAGTGCCGATCCTCCAGTGTC-3', 5'-CCCTTGCTTCCTTCTGCTGTCACTT-3' (Itga11 fl allele: 370 bp; Itga11 + allele: 280 bp).
Integrin binding assay
Integrin binding assays were performed as described (Nishiuchi et al., 2006) . Microtiter plates were coated with 10nM recombinant human Osteolectin, recombinant human Pro-Collagen 1a (R&D Systems), or Bovine Serum Albumin (BSA, Sigma A3156) overnight at 4°C, and then blocked with 10 mg/ml BSA. Recombinant human osteolectin was purified from 293 cells stably expressing Flag-tagged human osteolectin as described (Yue et al., 2016) , and 6xHis tagged recombinant human integrin heterodimers were purchased from R&D Systems.
The plates were incubated with integrins in TBS buffer (50 mM Tris-Cl, pH 7.5 150 mM NaCl) with 1 mM MnCl2, then washed with TBS containing 1 mM MnCl2, 0.1% BSA, and 0.02% Tween 20, followed by quantification of bound integrins by an enzyme-linked immunosorbent assay using an anti-His tag monoclonal antibody (Thermo Scientific, clone 4E3D10H2/E3) followed by a horseradish peroxidase-conjugated anti-mouse secondary antibody. After washing, bound HRP was detected using SureBlue TMB Microwell Peroxidase Substrate (KPL) and the reaction was stopped with TMB stop solution (KPL). The optical density was measured at 450 nm.
MicroCT analysis
MicroCT analysis was performed using the same settings as previously described (Yue et al., 2016) . Based on previously described methods (Bouxsein et al., 2010) , mouse femurs were dissected, fixed overnight in 4% paraformaldehyde (Thermo Fisher Scientific) and stored in 70% ethanol at 4°C. Femurs and lumbar vertebrae were scanned at an isotropic voxel size of 3.5 mm and 7 mm, respectively, with peak tube voltage of 55 kV and current of 0.145 mA (µCT 35; Scanco). A three-dimensional Gaussian filter (s = 0.8) with a limited, finite filter support of one was used to suppress noise in the images, and a threshold of 263-1000 was used to segment mineralized bone from air and soft tissues. Trabecular bone parameters were measured in the distal metaphysis of the femurs. The region of interest was selected from below the distal growth plate where the epiphyseal cap structure completely disappeared and continued for 100 slices toward the proximal end of the femur. Contours were drawn manually a few voxels away from the endocortical surface to define trabecular bones in the metaphysis.
Cortical bone parameters were measured by analyzing 100 slices in mid-diaphysis femurs.
Statistical analysis
Numbers of experiments noted in figure legends reflect independent experiments performed on different days. Mice were allocated to experiments randomly and samples processed in an arbitrary order, but formal randomization techniques were not used. Prior to analyzing the statistical significance of differences among treatments we tested whether data were normally distributed and whether variance was similar among treatments. To test for normality, we performed the Shapiro-Wilk tests. To test whether variability significantly differed among treatments we performed F-tests (for experiments with two treatments) or Levene's median tests (for experiments with more than two treatments). When the data significantly deviated from normality (P < 0.01) or variability significantly differed among treatments (P < 0.05), we log2-transformed the data and tested again for normality and variability. If the transformed data no longer significantly deviated from normality and equal variability, we then performed parametric tests on the transformed data. If the transformed data still significantly deviated from normality or equal variability, we performed non-parametric tests on the nontransformed data. Data from the same cell culture experiments were always paired for statistical analysis. Mouse littermates were paired for statistical analysis.
To assess the statistical significance of a difference between two treatments, we used paired two-tailed Student's t-tests (when a parametric test was appropriate) or Wilcoxon's tests (when a non-parametric test was appropriate). To assess the statistical significance of differences between more than two treatments, we used one-way or two-way repeated measures ANOVAs (when a parametric test was appropriate) followed by post-hoc tests including Dunnett's, Sidak's, and Tukey's tests depending on the experimental settings and planned comparisons, or multiple Wilcoxon's tests followed by Holm-Sidak's method for multiple comparisons adjustment (when a non-parametric test was appropriate). Relative mRNA levels were always log2-transformed before any statistical tests were performed. All statistical analyses were performed with Graphpad Prism 7.02. All data represent mean ± standard deviation (*p<0.05, **p<0.01, ***p<0.001).
Bone marrow digestion and CFU-F assay
As previously described (Yue et al., 2016) , mouse femurs and tibias were cut at both ends to flush out intact marrow plugs. Both the flushed plugs and crushed bone metaphyses were subjected to two rounds of enzymatic digestion in prewarmed digestion buffer containing 3 mg/ml type I collagenase (Worthington), 4 mg/ml dispase (Roche Diagnostic) and 1 U/ml DNase I (Sigma) in HBSS with calcium and magnesium, at 37°C for 15 min each round. During each round of digestion, the suspension was vortexed six times for 10 seconds each time at speed level 3 using a Vortex-Genie 2 to promote more complete dissociation. Dissociated cells were transferred into a tube with staining medium (HBSS without calcium and magnesium + 2% fetal bovine serum) and 2 mM EDTA to stop the digestion. Cells were then centrifuged, resuspended in staining medium, and passed through a 90 µm nylon mesh to filter undigested plugs or bone.
To form CFU-F colonies, freshly dissociated bone marrow cell suspensions were plated at clonal density in 6-well plates (5 x 10 5 cells/well) or 10 cm plates (5 x 10 6 cells/dish) with DMEM (Gibco) plus 20% fetal bovine serum (Sigma F2442), 10 mM ROCK inhibitor (Y-27632, Selleck), and 1% penicillin/streptomycin (Invitrogen) at 37°C in gas-tight chambers (Billups-Rothenberg) with 1% O2 and 6% CO2 (with balance Nitrogen) to maintain a low oxygen environment that promoted survival and proliferation (Morrison et al., 2000) . The CFU-F culture dish was rinsed with HBBS without calcium and magnesium and replenished with freshly made medium on the second day after plating to wash out contaminating macrophages. Cultures were then maintained in a gas-tight chamber that was flushed daily for 1 minute with a custom low oxygen gas mixture (1% O2, 6% CO2, balance Nitrogen). The culture medium was changed every 4 days. To count CFU-F colonies, the cultures were stained with 0.1% Toluidine blue in 4% formalin solution eight days after plating.
in vitro differentiation assay
The osteogenic potential of primary CFU-F cells, human bone marrow stromal cells, and MC3T3-E1 cells was assessed by plating the cells into 48-well plates (25,000 cells/cm 2 ). On the second day after plating, the culture medium was replaced with osteogenic differentiation medium (StemPro Osteogenesis Differentiation kit, Gibco). Cells were maintained in the differentiation medium, with medium change every other day for 14 days for primary CFU-F cells and MC3T3-E1 cells before differentiation was assessed. For human bone marrow stromal cells, the culture medium was changed every 3 days for 21 days. Osteoblastic differentiation was detected by staining with Alizarin red S (Sigma). To quantitate Alizarin red staining, the stained cells were rinsed with PBS, and extracted with 10% (w/v) cetylpyridinium chloride in 10 mM sodium phosphate, pH 7.0 for 10 minutes at room temperature. Alizarin red in the extract was quantitated by optical density measurement at 562 nm.
The adipogenic potential of CFU-F cells was assessed by plating them into 48-well plates (25,000 cells/cm 2 ). On the second day after plating, the culture medium was replaced with adipogenic differentiation medium (StemPro Adipogenesis Differentiation Kit, Gibco) and the cultures were allowed to differentiate for 14 days, with culture medium changed every 3 days. Adipocyte differentiation was detected by staining with Oil red O (Sigma). To quantitate the amount of Oil red O staining, cells were rinsed with PBS, and extracted with 100% isopropanol for 10 minutes at room temperature. Oil red O in the extract was quantitated by optical density measurement at 500 nm.
The chondrogenic potential of CFU-F cells was assessed by centrifuging 2 x 10 5 cells to form cell pellets, which were then cultured in chondrogenic medium (StemPro chondrogenesis differentiation kit; Gibco) for 21 days. The culture medium was changed every 3 days.
Chondrocyte formation within the cell pellets was assessed by cryosectioning and Toluidine blue staining as described (Robey et al., 2014) .
Calcein double labeling and histomorphometry analysis
As previously described (Egan et al., 2012) , mice were injected intraperitoneally with 10mg/kg body weight of calcein, dissolved in 0.15 M NaCl plus 2% NaHCO3 in water, at day 0 and day 7. Mice were sacrificed on day 9. Mouse tibias were fixed overnight in 4% paraformaldehyde at 4°C, dehydrated in 30% sucrose at 4°C for two days and sectioned without decalcification (7 µm sections). Mineral apposition rates were determined as previously described (Egan et al., 2012) .
ELISA assays
The bone resorption rate was determined by measuring urinary levels of deoxypyridinoline (DPD) using a MicroVue DPD ELISA Kit (Quidel). The DPD values were normalized to urinary creatinine levels using the MicroVue Creatinine Assay Kit (Quidel). The ELISA assay for Osteolectin was described previously (Yue et al., 2016) . Table S1. Markers used to isolate bone marrow cell populations. Stem and progenitor cell populations were isolated from mouse bone marrow by flow cytometry using the listed markers.
Lineage (Lin) markers used to isolate Lineage negative cell populations were CD2, CD3, CD5, CD8, Ter119, Gr-1, and B220. (Li et al., 1996) 
Pre-pro-B Cells
Prepro-B B220 + , CD43 + , CD24 -, IgM - (Li et al., 1996) A Figure 
